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Abstract 
Background 
Immunosuppression is required in kidney transplantation to prevent rejection and prolong graft 
survival. We conducted an economic evaluation to support the National Institute for Health and Care 
Excellence in developing updated guidance on the use of immunosuppression, incorporating new 
immunosuppressive agents, and addressing changes in pricing and the evidence base. 
Methods 
A discrete-time state transition model was developed to simulate adult kidney transplant patients 
over their lifetime. Sixteen different regimens were modelled to assess the cost-effectiveness of 
basiliximab and rabbit anti-thymocyte globulin (rabbit ATG) as induction agents (with no antibody 
induction as a comparator), and immediate-release tacrolimus, prolonged-release tacrolimus, 
mycophenolate mofetil, mycophenolate sodium, sirolimus, everolimus and belatacept as 
maintenance agents (with ciclosporin and azathioprine as comparators). Graft survival was 
extrapolated from acute rejection rates, graft function and post-transplant diabetes rates, all 
estimated at 12 months post-transplantation. NHS and personal social services costs were included. 
Cost-effectiveness thresholds of £20,000 and £30,000 per quality-adjusted life year (QALY) were 
used. 
Results 
Basiliximab was predicted to be more effective and less costly than rabbit ATG and induction without 
antibodies. Immediate-release tacrolimus and mycophenolate mofetil were cost-effective as 
maintenance therapies. Other therapies were either more expensive and less effective, or would 
only be cost-effective if a threshold in excess of £100,000 per QALY were used. 
Conclusions 
A regimen comprising induction with basiliximab, followed by maintenance therapy with immediate-
release tacrolimus and mycophenolate mofetil, is likely to be effective for uncomplicated adult 
kidney transplant patients and a cost-effective use of NHS resources. 
Keywords 
Adults; Cost-effectiveness; Cost–utility; Economic model; Immunosuppression; Kidney 
transplantation; Renal transplantation 
Key points  
 An economic model was developed to determine the cost-effectiveness of agents for induction 
and maintenance immunosuppression in adult kidney transplantation. 
 At conventional cost-effectiveness thresholds, induction therapy with basiliximab, and 
maintenance therapy with immediate-release tacrolimus and mycophenolate mofetil were 
found to be cost-effective. 
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Introduction 
Kidney transplantation is the preferred form of renal replacement therapy for most patients who 
have end stage renal disease, with clinical and economic benefits over dialysis [1]. Kidney transplant 
recipients (KTRs) take immunosuppressive drugs to prevent their immune system from rejecting or 
damaging the graft [2]; a number of such drugs have received European marketing authorisation 
recently. The costs of older drugs have also fallen following patent expiry. 
Patients can vary significantly in their needs, and a patient-centred approach is needed to prolong 
graft survival and manage comorbidities. Nevertheless, it is important to establish which 
immunosuppressive drugs are likely to be cost-effective in the majority of patients, so that limited 
healthcare resources can be targeted towards more complex KTRs and patients elsewhere in the 
health system. 
The National Institute for Health and Care Excellence (NICE) technology appraisal processes seek 
evidence on the clinical and cost-effectiveness of treatments for use in the NHS in England [3] to 
produce guidance with statutory reimbursement requirements. This economic evaluation was 
conducted to support the technology appraisal of immunosuppressive drugs in adult KTRs [4]. A 
systematic review of the clinical effectiveness of immunosuppressive therapy in adult KTRs was 
conducted [5]; our analysis is informed by the results of the systematic review. 
This economic evaluation sought to identify cost-effective induction and maintenance 
immunosuppressive regimens for adult KTRs. It is a cost–utility study in which health benefits are 
expressed in quality-adjusted life years (QALYs), which encapsulate both quantity and quality of life 
[6]. Cost-effectiveness thresholds of £20,000 and £30,000 per QALY were used. It is a model-based 
economic evaluation, allowing for extrapolation from clinical trial endpoints, synthesis of data from 
multiple sources, and exploration of the impact of different assumptions on results. 
Methods 
Target population 
The target population was adult patients undergoing kidney transplantation. Multi-organ transplant 
recipients were not included. The treatment of acute rejection was also not within the scope of the 
economic evaluation. 
In the base case analysis, a cohort of 50-year-old patients was modelled (the median age at 
transplantation was 50.5 years in the UK in 2012 [7]). 62% were men (based on data from 2007–
2012) [8]. The body weight of KTRs was assumed to be 70.2 kg (standard deviation 1.2 kg), estimated 
from reported body weights in RCTs [5]. 
Setting and location 
Patients in the NHS are transplanted as inpatients in hospital-based transplant units. After being 
discharged they are managed through outpatient clinics with a transplant surgeon or nephrologist. 
Shared management arrangements may be put in place with primary care physicians, but hospital 
nephrologists retain responsibility for prescribing. 
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Perspective 
Costs were included from an NHS and personal social services perspective, meaning that societal 
costs (e.g., lost productivity) and other public sector costs (e.g., lost tax revenue) were not included. 
The perspective on outcomes was direct health effects on patients. Costs and QALYs were 
discounted at 3.5% per year. These are the preferred perspectives for NICE technology appraisals [6]. 
Interventions and comparators 
For induction therapy, the evaluation compared basiliximab, rabbit anti-thymocyte globulin (rabbit 
ATG) and induction without mono- or polyclonal antibodies. For maintenance therapy, the model 
compared immediate-release tacrolimus (IR-Tacrolimus), prolonged-release tacrolimus (PR-
Tacrolimus), mycophenolate mofetil (MMF), mycophenolate sodium (MPS), sirolimus, everolimus, 
belatacept and maintenance with a calcineurin inhibitor with or without an antiproliferative agent. 
Alemtuzumab was excluded from the NICE scope since it does not have European marketing 
authorisation. 
Sixteen regimens were identified as being appropriate for evaluating the cost-effectiveness of all the 
interventions (Table 1). These were identified as being current or potential future practice in the 
NHS and having a significant amount of RCT evaluation. Steroid avoidance was not within scope of 
the appraisal, so all regimens also include low dose corticosteroids. 
Health outcomes 
The main health outcome of the economic evaluation was QALYs. Other outcomes included overall 
survival (life expectancy) and graft survival. 
Model structure 
KTRs were assumed to be in one of three health states: FUNCTIONING GRAFT, GRAFT LOSS or DEATH (Figure 
1). 
Up to two retransplantations were modelled, which could take place from the GRAFT LOSS state. For 
the initial graft only, pre-emptive retransplantation from the FUNCTIONING GRAFT state was also 
modelled. The rate of retransplantations (104 per 1,000 patient years [8]) was assumed to be 
constant below age 65, then decrease linearly, reaching zero by age 80. 
A cycle length of three months was used, and transitions were modelled as occurring midway 
through each cycle. A time horizon of 50 years was used for the economic evaluation, when 
surviving KTRs would be aged 100. 
Short-term graft survival (first year post-transplantation) was estimated using a proportional odds 
statistical model. Baseline graft survival was estimated from the UK Transplant Registry standard 
national organ transplant dataset [8]. A regimen of basiliximab induction with IR-Tacrolimus and 
MMF maintenance was assumed to represent the baseline as it is believed to be the most commonly 
used regimen. The odds ratios for graft survival at 12 months (Table 2) were used to estimate 
survival for the other arms within the first year. 
Subsequent graft survival was estimated using a proportional hazards statistical model. Baseline 
graft survival was extrapolated from the UK Transplant Registry standard national organ transplant 
dataset, using a Weibull model. The Weibull model fit was assessed using the Akaike information 
criterion (AIC) and visual inspection of the survival curves and Cox–Snell residuals. Other parametric 
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models were assessed and the Weibull performed best on AIC, with the exception of the generalised 
gamma model, which produced almost identical long-term survival curves to the Weibull model. 
Proportional hazards were applied on the basis of estimated graft function (estimated glomerular 
filtration rate; eGFR) [9], acute rejection and post-transplantation diabetes mellitus (PTDM) [10] (all 
measured at 12 months post-transplantation). 
Effectiveness 
As part of the technology appraisal process a systematic review of the clinical effectiveness of 
immunosuppressive therapy in adult KTRs was performed [5]. 
A total of 86 RCTs were included, 11 evaluating induction agents, 73 evaluating maintenance agents 
and two evaluating both. 
Four outcomes (biopsy-proven acute rejection, BPAR; graft loss; mortality; graft function) at one 
year were synthesised using fixed effects network meta-analyses (separately for induction agents 
and maintenance regimens). The results of these network meta-analyses are given in Table 2. 
Further network meta-analyses of these studies were conducted for the rate of PTDM, dyslipidaemia 
and cytomegalovirus (CMV) infection to support the economic modelling (Table 3 and Table 4). 
These analyses were conducted on individual immunosuppressive agents rather than regimens. 
Utilities 
An age-dependent utility function was used in the calculation of QALYs, estimated from the Health 
Survey for England [11, 12]. From this baseline, utility decrements were applied to patients with 
functioning grafts and patients receiving dialysis. These were derived from a systematic review and 
meta-analysis [13]. A utility decrement was also applied for patients with PTDM [14]. 
Equation 1 describes the utility function, where Age is measured in years (since birth). 
U = 0.967981 − 0.001807 × Age − 0.000010 × Age² + 0.023289 × I(Male) 
− 0.053 × I(Functioning graft) 
− 0.277 × I(Haemodialysis) 
− 0.264 × I(Peritoneal dialysis) 
− 0.060 × I(PTDM) 
(1) 
Estimating resources and costs 
Drug acquisition 
Drug acquisition costs were drawn from the CMU eMit database [15] for immunosuppressive agents 
available as generics and from the British National Formulary [16] otherwise (Table 5). 
Immunosuppressant dosages were estimated based on the RCTs included in the systematic review 
[5] or from the summary of product characteristics (Table 6). 
Wastage was included for belatacept since vial sharing is not permitted, but not for other 
maintenance immunosuppressants, where it was assumed that there would be minimal wastage 
since these are tablets or capsules with a long shelf life which are taken over a long period of time. 
Wastage was not included for basiliximab as the dose is fixed. Wastage was also not included for 
rabbit ATG, although it is a possibility. 
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KTRs at high risk of CMV infection received 200 days of prophylaxis with valganciclovir. KTRs at 
intermediate risk receiving rabbit ATG received 4½ months prophylaxis. 
Drug administration 
Most immunosuppressants are administered orally, incurring no drug administration cost. 
Basiliximab, rabbit ATG and belatacept are administered parenterally. Basiliximab and rabbit ATG 
were assumed to be delivered by intravenous infusion [17] with estimated costs of £229 and £326 
for the first and subsequent infusions respectively [18]. Belatacept is also delivered by intravenous 
infusion at a cost of £168 per infusion [18]. 
Renal replacement therapy 
All patients without a functioning graft were assumed to be receiving haemodialysis or peritoneal 
dialysis, with the proportion receiving each dependent on age [19]. Haemodialysis patients were 
assumed to require one temporary access procedure (£823 [18]) and one permanent access 
procedure (arteriovenous fistula; £1,946 [18]). Peritoneal dialysis patients were assumed to require 
one permanent access procedure (£1,101 [18]). 
Haemodialysis was estimated to cost on average £24,400 per year, and peritoneal dialysis £24,000 
per year [18]. 
The total average cost of retransplantation was estimated to be £27,000, of which £16,000 is the 
cost of transplant surgery [18]. For living donor kidney transplantation (34.9%) there were estimated 
costs of £8,900 for screening, pre-transplantation work up of the donor and the explant procedure 
[18]. For deceased donor kidney transplantation (65.1%) there were estimated costs of staffing, 
consumables and transport for retrievals [20]. 
Clinical events 
Acute rejection episodes were estimated to cost £3,557 on average based on an unpublished 
microcosting study submitted by the pharmaceutical company Bristol–Myers Squibb in their 
submission to NICE [21]. Patients are susceptible to multiple acute rejection episodes, and an 
average of 1.19 episodes was assumed for patients experiencing at least one episode [22]. 
CMV infection was estimated to cost £3,009 based on the same microcosting study [21]. It was 
assumed that patients would experience at most one CMV infection. 
Patients with PTDM incurred costs of anti-diabetic treatment (metformin) and complications 
(average annual costs of £2,084 [23]). 
Patients experiencing graft loss were assumed to commence dialysis, and a certain proportion were 
assumed to have their graft removed (explant surgery £4,966 [18]); this proportion was small for 
patients whose grafts had functioned for over a year before graft loss. 
KTRs with dyslipidaemia were assumed to have annual visits to dietetics outpatients clinics (£63 [18]) 
and their primary physician (£51 [24]) in relation to dyslipidaemia. The cost of medication with 
statins was also included. 
It was assumed that anaemia requiring treatment with erythropoiesis stimulating agents would 
occur in 5.2% of patients and these would require a mean weekly dose of 5,832 IU [25]. 
Immunosuppressive agents in adult kidney transplantation in the NHS: a model-based economic 
evaluation 
7 
 
Monitoring 
KTRs receive monitoring on a frequent basis, which is gradually tapered for KTRs with stable grafts. 
In the model KTRs attended clinics and received the following monitoring: full blood count; renal 
profile; liver function tests; therapeutic drug monitoring; and, on separate schedules, viral 
quantitative PCR (CMV, Epstein–Barr virus, BK virus). The frequency of clinic visits and routine 
monitoring tests was based on an unpublished retrospective observational study submitted by 
Bristol–Myers Squibb in their submission to NICE [26]. 
Currency and price date 
All costs are presented in 2014/15 pounds sterling (GBP; £). No prices required currency conversion. 
Prices were inflated to 2014/15 prices where necessary using the Hospital and Community Health 
Services pay and prices index to 2013/14 and then by a further year using average inflation over the 
previous three years [24]. 
Analysis 
Cost–utility analyses were conducted at: 
1. The level of individual agents by comparing regimens which differed only by one agent; 
2. The level of regimens in a fully incremental analysis. 
Deterministic and probabilistic sensitivity analyses were conducted. 
Results 
Effectiveness 
An immunosuppressive regimen comprising induction with basiliximab and maintenance with 
belatacept and MMF was predicted to give the longest graft survival (18.0 years) and greatest overall 
survival (23.2 years), and most discounted QALYs (11.29). A regimen comprising induction without 
mono- or polyclonal antibodies and maintenance with ciclosporin and azathioprine was predicted to 
give the shortest graft survival (15.0 years), while a regimen with IR-Tacrolimus and sirolimus 
maintenance was predicted to give the lowest overall survival (22.1 years) and least discounted 
QALYs (10.6). 
Figure 2 demonstrates that graft survival was usually associated with overall survival, although 
regimens with elevated rates of PTDM have reduced overall survival due to the increased risk of 
death with a functioning graft. 
Cost-effectiveness 
The total costs and QALYs for each regimen are shown in Table 7. 
Induction agents 
Basiliximab and rabbit ATG were compared alongside induction without mono- or polyclonal 
antibodies (“no induction”) in three comparisons (with different maintenance regimens). Across the 
comparisons, rabbit ATG was more effective (more QALYs) than no induction and basiliximab was 
more effective than rabbit ATG. Rabbit ATG was the most costly, followed by no induction, with 
Immunosuppressive agents in adult kidney transplantation in the NHS: a model-based economic 
evaluation 
8 
 
basiliximab induction being least costly. Basiliximab was less costly and more effective than the 
other treatment options and was therefore dominant. 
These results were confirmed in probabilistic analyses, with basiliximab predicted to be cost-
effective in 93–95% of simulations. 
Maintenance agents 
IR-Tacrolimus was compared to ciclosporin in four comparisons and was predicted to be less costly 
in all four. When used with no induction and with azathioprine, IR-Tacrolimus was predicted to be 
more effective and was therefore dominant. In the other three comparisons, IR-Tacrolimus was 
predicted to be marginally less effective (longer graft survival but reduced QALYs due to increased 
incidence of PTDM), but with the ICER for ciclosporin versus IR-Tacrolimus over £100,000/QALY. 
IR-Tacrolimus was compared to PR-Tacrolimus in one comparison and was predicted to be 
dominant. In another comparison IR-Tacrolimus was compared to sirolimus and belatacept, and was 
predicted to dominate sirolimus and be cost-effective versus belatacept (ICER of belatacept 
>£400,000/QALY). 
Sirolimus was also compared to azathioprine and MMF, and was predicted to be dominated by both. 
Everolimus was compared to azathioprine and MMF, and was predicted to be more costly and more 
effective (ICER >£1m/QALY). 
MMF was compared to azathioprine in four comparisons and was predicted to be dominant in all 
four. MPS was compared to azathioprine and MMF, and was predicted to be more costly and more 
effective (ICER £144,000/QALY). 
Deterministic analyses demonstrated that only IR-Tacrolimus and MMF are cost-effective at 
thresholds of £20,000 and £30,000 per QALY. 
Regimens 
The only cost-effective regimen when all regimens were compared simultaneously comprised 
basiliximab induction and IR-Tacrolimus and MMF maintenance (Table 8). Three other regimens 
were on the cost-effectiveness frontier, but with ICERs in excess of £100,000/QALY. 
Analyses of uncertainty 
Probabilistic sensitivity analyses were conducted, which confirmed that at cost-effectiveness 
thresholds of £20,000 and £30,000 per QALY, IR-Tacrolimus and MMF were expected to give the 
highest net health benefit (once additional costs have been exchanged for health forgone by 
patients elsewhere in the health system) and were most likely to be cost-effective. 
To determine the importance of the impact of PTDM on cost-effectiveness, a scenario analysis was 
conducted in which no disutility was applied to patients with PTDM. Basiliximab, IR-Tacrolimus and 
MMF remained the only cost-effective agents, and IR-Tacrolimus dominated ciclosporin in all 
comparisons. 
The importance of the surrogate relationship from graft function, acute rejection and PTDM to graft 
survival was investigated by varying the duration for which these outcomes affected graft survival 
through proportional hazards. As the surrogate relationship was weakened, ciclosporin became 
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optimal (instead of IR-Tacrolimus), then induction without mono- or polyclonal antibodies became 
optimal (instead of basiliximab). 
Discussion 
We found that basiliximab, immediate-release tacrolimus and mycophenolate mofetil are likely to be 
optimal immunosuppressants (in terms of cost-effectiveness) for the majority of adult KTRs in the 
NHS. 
These results should be considered alongside the need to tailor therapy to an individual patient’s 
needs. For some patients there may be a different balance of potential benefits and harms from 
different immunosuppression regimes compared to “the average patient” [27]. It was not possible to 
perform subgroup analyses of effectiveness for this economic evaluation because subgroup analyses 
of effectiveness were not conducted in the systematic review [5], since these were not reported by 
the included trials. 
Tacrolimus, although an effective immunosuppressant, is also diabetogenic [28]. For patients at risk 
of diabetes or at risk of complications from diabetes, it may be more effective and cost-effective to 
use ciclosporin instead, since diabetes is associated with adverse events and increased mortality. 
Ciclosporin offered the second-best net health benefit after immediate-release tacrolimus. 
Tacrolimus (along with ciclosporin) is also associated with nephrotoxicity. If dose reduction is not 
able to halt chronic allograft injury due to nephrotoxicity then clinicians may consider withdrawal of 
tacrolimus in low immunological risk patients, or switching to an alternative therapy, such as 
sirolimus, everolimus or belatacept [28]. Our economic evaluation suggests that for such patients, 
sirolimus would be most cost-effective. 
Mycophenolate mofetil has been associated with gastrointestinal side effects, including diarrhoea, 
nausea and vomiting [28] – these can lead to impaired absorption and decreased adherence, which 
could cause graft loss. In such circumstances our economic evaluation suggests that azathioprine 
should first be considered as a replacement (mycophenolate sodium is estimated to cost over 
£50,000 per QALY gained compared to azathioprine), although this is not based on evidence in 
patients with mycophenolate mofetil intolerance. 
Rabbit ATG has been recommended in guidelines (e.g., KDIGO [28]) for induction therapy in kidney 
transplant recipients at high immunological risk. We were not able to separately assess cost-
effectiveness in such patients in this evaluation, because there were no studies comparing rabbit 
ATG to basiliximab or placebo in patients with high immunological risk identified in the review of 
clinical effectiveness [5]. The review did not include daclizumab as an intervention or comparator 
(since its marketing authorisation was withdrawn), but some other reviews (e.g., Webster et al. 2010 
[29]) have included daclizumab and assumed a class effect of interleukin-2 receptor antagonists 
(IL2Ra; basiliximab and daclizumab). A study by Noël et al. [30] compared daclizumab to rabbit ATG 
in patients with high immunological risk. It found that patients inducted with rabbit ATG had a 
significantly lower risk of biopsy-proven acute rejection (odds ratio 0.47, 95% CI 0.25 to 0.91). In the 
daclizumab group 27% of patients experienced biopsy-proven acute rejection. We conducted a 
scenario analysis in which we incorporated this data (assuming a class effect), and found that 
basiliximab continued to be less costly and more effective (in terms of QALYs) and this finding was 
robust to changes in baseline graft survival. It is possible that further studies comparing ATG to IL2Ra 
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in patients at high immunological risk, with longer follow-up, could demonstrate sufficient 
effectiveness to make rabbit ATG cost-effective. 
Our results contrast with those in a recently published cost–utility study by Muduma et al., which 
found that sirolimus as part of a calcineurin inhibitor minimisation strategy would be cost-effective 
compared to immediate-release tacrolimus, prolonged-release tacrolimus, ciclosporin and 
belatacept [31]. Muduma et al. used a 25-year time horizon, compared to the 50-year time horizon 
in this evaluation (although the results of this evaluation are not significantly altered by adopting a 
25-year time horizon). Muduma et al. also did not account for the effect of short-term graft function 
on long-term graft survival, and they have not reported the sources or values of effectiveness 
estimates. 
A limitation of our evaluation is the poor quality of the underpinning clinical effectiveness literature. 
RCTs of immunosuppression in kidney transplantation are plentiful, but are often underpowered for 
key clinical outcomes (graft loss and mortality) and have limited follow-up [5]. Baseline graft survival 
in this evaluation was extrapolated from mature registry data [8], but treatment effects were 
assessed at one year post-transplantation. For regimens where progressive loss of graft function is 
not typically observed (those not including calcineurin inhibitors), this may have led to an 
underestimation of long-term graft survival. 
Comparative effectiveness analyses of kidney transplant registries could overcome issues of 
statistical power and limited follow-up, and include patient groups who are typically excluded from 
RCTs (such as the elderly and the multi-morbid). It is possible that adjusted treatment effects may be 
estimated for some agents (those which are widely prescribed) through the use of advanced 
statistical techniques [32]. Analyses of these registries may also give greater insight into the 
prognostic value of graft function in patients receiving different immunosuppressive regimens. 
A number of factors will limit the generalisability of these results to other settings (e.g., other 
countries) [33, 34], due to differences in costs, service designs, valuation of health outcomes and 
willingness-to-pay. To facilitate economic evaluation of immunosuppressive agents for kidney 
transplantation in other settings, we have made the underlying economic model free to download 
under a Creative Commons license [35]. 
Future assessments of immunosuppressive agents may consider the effectiveness and cost-
effectiveness of immunosuppressive agents in subgroups (potentially including non-RCT and 
individual patient data). Most RCTs did not report subgroups, or reported them poorly, but clinicians 
and healthcare providers would likely benefit from high-quality evidence of the effectiveness and 
cost-effectiveness of immunosuppressive agents in certain subgroups, e.g., those at high 
immunological risk. 
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Tables 
Table 1: Regimens considered in the economic evaluation 
With induction without mono- or 
polyclonal antibodies 
With basiliximab induction With rabbit ATG induction 
 Ciclosporin + mycophenolate 
mofetil 
 Ciclosporin + azathioprine 
 Immediate-release 
tacrolimus + mycophenolate 
mofetil 
 Immediate-release 
tacrolimus + azathioprine 
 Ciclosporin + everolimus 
 Immediate-release 
tacrolimus + sirolimus 
 Prolonged-release tacrolimus 
+ mycophenolate mofetil 
 Ciclosporin + mycophenolate 
mofetil 
 Ciclosporin + azathioprine 
 Immediate-release 
tacrolimus + mycophenolate 
mofetil 
 Sirolimus + mycophenolate 
mofetil 
 Belatacept + mycophenolate 
mofetil 
 Ciclosporin + mycophenolate 
sodium 
 Ciclosporin + mycophenolate 
mofetil 
 Ciclosporin + azathioprine 
 Immediate-release 
tacrolimus + mycophenolate 
mofetil 
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Table 2: Median treatment effects used in the economic model from fixed effects network meta-
analyses 
Treatment 
(regimen) 
Odds ratioa (95% CrI) Mean differenceb 
(95% CrI) 
 Biopsy-proven 
acute rejection 
Graft loss Patient death Graft function 
(eGFR, 
ml/min/1.73 m²) 
Induction agent (versus placebo/no induction) 
Basiliximab 0.52 (0.41, 0.65) 0.82 (0.56, 1.18) 0.99 (0.53, 1.85) 2.11 (−0.45, 4.68) 
Rabbit ATG 0.36 (0.24, 0.54) 0.77 (0.39, 1.47) 0.84 (0.33, 2.07) −3.95 (−11.80, 
3.94) 
Maintenance regimen (versus ciclosporin and azathioprine) 
IR-Tacrolimus and 
azathioprine 
0.58 (0.36, 0.93) 1.13 (0.67, 2.15) 1.38 (0.74, 2.60) 9.31 (4.32, 14.28) 
Ciclosporin and 
mycophenolatec 
0.47 (0.25, 0.88) 0.76 (0.35, 1.44) 0.94 (0.45, 1.95) 1.61 (−4.16, 7.41) 
IR-Tacrolimus and 
mycophenolatec 
0.40 (0.19, 0.79) 0.69 (0.28, 1.55) 1.53 (0.63, 3.71) 6.53 (0.38, 12.68) 
Belatacept and 
mycophenolatec 
0.81 (0.34, 1.94) 0.62 (0.20, 1.78) 0.47 (0.15, 1.38) 10.54 (2.47, 18.66) 
Ciclosporin and 
everolimus 
0.46 (0.21, 0.99) 0.63 (0.20, 1.58) 1.40 (0.52, 3.65) 4.85 (−2.84, 12.58) 
IR-Tacrolimus and 
sirolimus 
0.38 (0.16, 0.93) 1.19 (0.38, 3.35) 1.38 (0.49, 3.88) −0.34 (−8.53, 7.85) 
Sirolimus and 
mycophenolatec 
0.43 (0.22, 0.92) 1.06 (0.38, 2.43) 1.72 (0.68, 4.31) 3.84 (−2.72, 10.43) 
Key: (Rabbit) ATG, rabbit anti-thymocyte globulin; CrI, credible interval; eGFR, estimated glomerular 
filtration rate; IR-Tacrolimus, immediate-release tacrolimus 
Notes: a, Odds ratio below one favours intervention; b, Mean difference above zero favours intervention; c, 
Mycophenolate mofetil or mycophenolate sodium; Bold face indicates 95% CrI does not contain one 
(for odds ratio) or zero (for mean difference) 
Source: Jones-Hughes et al. 2016 [5] 
 
Table 3: Impact of maintenance agents on incidence of post-transplant diabetes used in the 
economic model 
Maintenance agent Odds ratio of PTDM incidence [Median (95% CrI)] 
IR-tacrolimus (Baseline) 
Immunosuppressive agents in adult kidney transplantation in the NHS: a model-based economic 
evaluation 
15 
 
PR-tacrolimus 1.18 (0.63, 2.23) 
Ciclosporin 0.44 (0.26, 0.66) 
Belatacept 0.19 (0.09, 0.39) 
Sirolimus 0.79 (0.51, 1.22) 
Mycophenolate mofetil (Baseline) 
Mycophenolate sodium 0.94 (0.27, 3.08) 
Sirolimus 1.60 (0.84, 3.10) 
Everolimus 0.95 (0.51, 1.78) 
Key: CrI, credible interval; IR-Tacrolimus, immediate-release tacrolimus; PR-tacrolimus, prolonged-release 
tacrolimus; PTDM, post-transplant diabetes 
Notes: Results from fixed effects models; Bold face indicates 95% CrI does not contain one 
 
Table 4: Impact of mTOR-I (sirolimus or everolimus) use on incidence of dyslipidaemia and 
cytomegalovirus infection in the economic model 
mTOR-I use Odds ratio of dyslipidaemia 
incidencea [Median (95% CrI)] 
Odds ratio of CMV incidenceb 
[Median (95% CrI)] 
None (Baseline) (Baseline) 
Sirolimus or everolimus 1.74 (1.43, 2.12)  
Sirolimus (with MMF)  0.45 (0.21, 1.01) 
Sirolimus (with IR-tacrolimus) or 
everolimus (with MPS) 
 0.31 (0.12, 0.89) 
Key: CMV, cytomegalovirus; CrI, credible interval; IR-tacrolimus, immediate-release tacrolimus; MMF, 
mycophenolate mofetil; MPS, mycophenolate sodium; mTOR-I, mechanistic target of rapamycin 
inhibitor 
Notes: a, Fixed effects model; b, Random effects model; Bold face indicates 95% CrI does not contain one 
 
Table 5: Unit costs of drug acquisition 
Agent Pack size Pack price Unit Price per unit 
Immunosuppressants     
Basiliximab (Simulect®, Novartis) 1× 20-mg vial £842.38 20 mg £842.38 
Rabbit ATG (Thymoglobuline®, Sanofi) 1× 25-mg vial £158.77 1 mg £6.35 
IR-tacrolimus (generic)   1 mg £0.5201 
PR-tacrolimus (Advagraf®, Astellas) 50× 5-mg capsule £266.92 1 mg £1.068 
Ciclosporin (generic)   1 mg £0.0165 
Mycophenolate mofetil (generic)   1 g £0.3774 
Mycophenolate sodium (Myfortic®, Novartis) 120× 180-mg tablet £96.72 1 mg £0.0045 
Azathioprine (generic)   1 mg £0.0011 
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Sirolimus (Rapamune®, Pfizer) 30× 2-mg tablet £172.98 1 mg £2.883 
Everolimus (Certican®, Novartis) 60× 0.25-mg tablet £148.50 1 mg £9.90 
Belatacept (Nulojix®, Bristol-Myers Squibb) 1× 250-mg vial £354.52 250 mg £354.52 
Prednisolone (generic)   1 mg £0.0033 
Infection prophylaxis     
Co-trimoxazole (Septrin®, Aspen) 100× 480-mg tablet £15.52 480 mg £0.1552 
Valganciclovir (Valcyte®, Roche) 60× 450-mg tablet £1,081.46 450 mg £18.02 
Anti-diabetics     
Metformin (generic)   500 mg £0.0054 
Statins     
Fluvastatin (generic)   1 mg £0.0022 
Pravastatin (generic)   1 mg £0.0026 
Simvastatin (generic)   1 mg £0.0003 
Key: IR-tacrolimus, immediate-release tacrolimus; PR-tacrolimus, prolonged-release tacrolimus 
 
Table 6: Immunosuppressant resource use 
Agent Concomitant 
treatment 
Mean daily dosea 
  First year Second year Thereafterb 
AZA CSA 102 mg 85 mg 85 mg 
AZA TAC 95 mg 84 mg 84 mg 
BEL MMF 9.0 vials per month 6.2 vials per month 6.2 vials per month 
CSA AZA 275 mg 206 mg 200 mg 
CSA EVL 274 mg 147 mg 147 mg 
CSA MMF/MPS 232 mg 198 mg 198 mg 
EVL CSA 2.7 mg 2.6 mg 2.0 mg 
MMF BEL 2.0 g 2.0 g 2.0 g 
MMF CSA 1.9 g 1.7 g 1.7 g 
MMF SRL 1.8 g 1.5 g 1.5 g 
MMF TAC/TAC-PR 1.8 g 1.5 g 1.5 g 
MPS CSA 1242 mg 1107 mg 1107 mg 
SRL MMF 4.1 mg 2.9 mg 2.7 mg 
SRL TAC 3.7 mg 2.8 mg 2.2 mg 
TAC AZA 9.6 mg 6.3 mg 5.7 mg 
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TAC MMF 7.3 mg 5.6 mg 5.6 mg 
TAC SRL 6.9 mg 4.9 mg 4.9 mg 
TAC-PR MMF 10.6 mg 6.3 mg 5.7 mg 
Key: AZA, azathioprine; BEL, belatacept; CSA, ciclosporin; EVL, everolimus; MMF, mycophenolate mofetil; 
MPS, mycophenolate sodium; SRL, sirolimus; TAC, immediate-release tacrolimus; TAC-PR, prolonged-
release tacrolimus 
Notes: a, For patient weighing 70.2 kg; b, Based on 24 months to 10 years 
 
Table 7: Total lifetime discounted costs and QALYs for all regimens 
Regimen Total discounted costs Total discounted QALYs 
Ciclosporin and MMF £97,400 10.91 
IR-tacrolimus and MMF £92,200 10.89 
Ciclosporin and azathioprine £101,600 10.77 
IR-tacrolimus and azathioprine £93,300 10.87 
Ciclosporin and everolimus £176,200 10.97 
IR-tacrolimus and sirolimus £125,500 10.60 
PR-tacrolimus and MMF £106,500 10.79 
Basiliximab, ciclosporin and MMF £95,200 11.02 
Basiliximab, IR-tacrolimus and MMF £90,400 10.99 
Basiliximab, ciclosporin and azathioprine £98,200 10.90 
Basiliximab, sirolimus and MMF £114,500 10.90 
Basiliximab, belatacept and MMF £209,400 11.29 
Basiliximab, ciclosporin and MPS £111,500 11.14 
Rabbit ATG, ciclosporin and MMF £101,900 10.93 
Rabbit ATG, IR-tacrolimus and MMF £97,100 10.90 
Rabbit ATG, ciclosporin and azathioprine £104,600 10.82 
Key: IR-tacrolimus, immediate-release tacrolimus; MMF, mycophenolate mofetil; MPS, mycophenolate 
sodium; QALY, quality-adjusted life year 
Notes: Total discounted costs rounded to nearest £100; Total discounted QALYs rounded to 2 decimal places 
 
Table 8: Cost-effectiveness results for regimens on the cost-effectiveness frontier (deterministic; 
base case) 
Regimen Total discounted 
costs 
Total discounted 
QALYs 
ICER (cost per QALY) 
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Basiliximab, IR-tacrolimus and MMF £90,400 10.99 — 
Basiliximab, ciclosporin and MMF £95,200 11.02 £131,000 
Basiliximab, ciclosporin and MPS £111,500 11.14 £144,000 
Basiliximab, belatacept and MMF £209,400 11.29 £626,000 
Key: ICER, incremental cost-effectiveness ratio (the cost per additional QALY); IR-tacrolimus, immediate-
release tacrolimus; MMF, mycophenolate mofetil; MPS, mycophenolate sodium; QALY, quality-
adjusted life year 
Notes: Total discounted costs rounded to nearest £100; Total discounted QALYs rounded to 2 decimal places; 
ICERs rounded to nearest £1,000 per QALY 
Figures 
 
Figure 1: Decision model diagram 
Key: FG, FUNCTIONING GRAFT; GL, GRAFT LOSS 
Notes: Dashed arrows indicate primary non-function; Arrows with unfilled heads indicate pre-emptive 
retransplantation; Self-links omitted for clarity 
   
FG1 
GL1 
FG2 
GL2 
FG3 
GL3 
Death 
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Figure 2: Mean graft survival and overall survival for regimens modelled in the economic 
evaluation 
Key: AZA, azathioprine; BAS, basiliximab; BEL, belatacept; CSA, ciclosporin; EVL, everolimus; MMF, 
mycophenolate mofetil; MPS, mycophenolate sodium; rATG, rabbit anti-thymocyte globulin; SRL, 
sirolimus; TAC, immediate-release tacrolimus; TAC-PR, prolonged-release tacrolimus 
Notes: Regimens are ordered by increasing overall survival from top to bottom. 
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Figure 3: Total discounted costs for regimens modelled in the economic evaluation 
Key: AZA, azathioprine; BAS, basiliximab; BEL, belatacept; CSA, ciclosporin; EVL, everolimus; MMF, 
mycophenolate mofetil; MPS, mycophenolate sodium; rATG, rabbit anti-thymocyte globulin; SRL, 
sirolimus; TAC, immediate-release tacrolimus; TAC-PR, prolonged-release tacrolimus 
Notes: Regimens are ordered by increasing total discounted costs from top to bottom. 
 
 
